NAD+ and NADH for ME/CFS: What the Trials Actually Show

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is defined by exactly the kind of symptom — profound, unrelenting fatigue with post-exertional crashes — that an "energy molecule" like NAD+ seems built to fix. Unsurprisingly, NAD+ drips, NMN, and NADH supplements are all marketed to people with ME/CFS. What sets this condition apart from most NAD+ marketing, though, is that one form of the molecule — oral NADH, the reduced form of NAD+ — has actually been run through placebo-controlled trials in ME/CFS patients, some of them dating back decades. So instead of pure mechanism, there is real (if modest) human data to weigh.

This page is the honest version: why NAD+/NADH is even a candidate, what the oral NADH trials and the larger CoQ10+NADH study actually found, and why "it's been tested" is still a long way from "it works." (We cover the closely related question of NAD+ for long COVID — which often overlaps with ME/CFS — separately in our NAD+ for long COVID review; this page focuses on the ME/CFS-specific NADH trials.)

Why NADH is even a candidate in ME/CFS

NAD+ (nicotinamide adenine dinucleotide) and its reduced partner NADH shuttle electrons through the reactions that turn food into ATP — the cell's energy currency. If a disease is fundamentally a problem of cellular energy production, propping up this pathway is an obvious thing to try. And ME/CFS does carry biochemical fingerprints that point this way: NAD+ falls with age and metabolic stress in human tissue ¹, NAD+ sits at the center of the energy and repair machinery that struggles in fatigue states ², and a dedicated review has mapped how the kynurenine pathway — the route the body uses to build NAD+ from tryptophan — appears disturbed in ME/CFS specifically ³. So the rationale is genuinely mechanism-based, not invented.

The catch is the one that haunts the entire NAD+ field: a plausible pathway is not a proven therapy. Here, at least, we don't have to argue from mechanism alone — we have trials.

The oral NADH trials: small, old, and mixed

The anchor study is a 1999 placebo-controlled crossover trial by Forsyth and colleagues, which gave 26 ME/CFS patients 10 mg of oral NADH (or placebo) daily for four weeks each ⁴. It reported that roughly 31% of patients improved on NADH versus about 8% on placebo — a positive signal that launched NADH's reputation in this space. But read it honestly: it was a small, short crossover study, the response was defined on a self-reported symptom score, and even the responders represented a minority. It is a hypothesis-generating result, not a definitive one.

A later open comparison by Santaella and colleagues (2004) pitted oral NADH against conventional therapy in ME/CFS and found NADH produced a faster early reduction in symptoms, though the difference faded over the longer follow-up ⁵. Useful, but it was not a rigorous placebo-controlled design, so it can't separate a true drug effect from expectation and natural fluctuation.

So the oral-NADH-alone evidence is best summarized as: two small studies, one randomized and one not, both decades old, both showing a modest early signal in a subset of patients — and neither large or modern enough to settle the question.

The stronger study tested a combination, not NADH alone

The most robust trial in this whole area didn't test NADH by itself. A 2021 randomized, double-blind, placebo-controlled trial by Castro-Marrero and colleagues enrolled 207 ME/CFS patients and gave them either 200 mg of coenzyme Q10 plus 20 mg of NADH daily, or matching placebo, for 12 weeks ⁶. The combination significantly reduced perceived cognitive fatigue and improved health-related quality of life versus placebo. An earlier randomized trial from the same group reported that CoQ10 plus NADH improved maximum heart rate during exercise testing ⁷.

These are the best controlled signals NAD+-adjacent therapy has in ME/CFS — genuinely randomized, double-blind, and reasonably sized. But two caveats are non-negotiable. First, they test a combination (CoQ10 + NADH), so the benefit can't be cleanly credited to NADH; CoQ10 is itself an established mitochondrial supplement. Second, the outcomes are subjective and physiological surrogates (fatigue scales, quality of life, heart-rate recovery), not hard functional endpoints like return-to-work or objective activity. A systematic review of randomized trials across CFS/ME drives the point home: the literature is small, heterogeneous, and has not established any single intervention as clearly effective ⁸.

What this is NOT: IV NAD+ and NMN for ME/CFS

Notice what's missing from all of the above. The trials use oral NADH, usually combined with CoQ10. They are not trials of intravenous NAD+ drips, and they are not trials of NMN — the two most aggressively marketed (and most expensive) options. There are no randomized outcome trials of IV NAD+ for ME/CFS, and NMN has not been shown to relieve ME/CFS fatigue in controlled studies. Extrapolating the modest oral-NADH/CoQ10 signal to justify a costly NAD+ IV is exactly the kind of leap the marketing makes and the data don't support.

That caution is reinforced by the broader NAD+ precursor literature, where raising the biomarker reliably fails to translate into felt benefit. Nicotinamide riboside raised NAD+ in older adults with mild cognitive impairment without improving cognition ⁹, and a meta-analysis of NAD+ precursors on metabolic-syndrome parameters found benefits limited and inconsistent despite reliably elevated NAD+ ¹⁰. "Higher NAD+" is simply not the same claim as "less fatigue." We unpack that gap in our pillar guide to NAD+ therapy evidence and in does NAD+ actually boost energy.

An honest bottom line for patients

• •The mechanism is plausible: ME/CFS shows disturbances in NAD+/kynurenine metabolism ³, and NAD+ is central to cellular energy ¹².
• •Oral NADH has actually been tested — a rarity in NAD+ marketing — but the trials are small, old, and mixed, with benefit in a subset ⁴⁵.
• •The strongest evidence is for CoQ10 + NADH together, from a 207-patient randomized trial ⁶ and an earlier exercise study ⁷ — modest, on subjective endpoints, and not attributable to NADH alone, within a small overall literature ⁸.
• •IV NAD+ and NMN have no ME/CFS outcome trials, and precursors broadly raise NAD+ without reliably improving how people feel ⁹¹⁰.

The fair reading: oral NADH (especially paired with CoQ10) is a low-cost, modestly-supported, worth-discussing option for ME/CFS — not a cure, and certainly not a reason to buy an expensive drip. If you're exploring it, do so with the clinician managing your condition, and start by understanding the whole field — see our NAD+ therapy evidence pillar, check the side effects of any precursor first, and see how products and providers compare on our NAD+ rankings hub.